TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›CGTX›Financials
Annual statements · SEC XBRL · FY2020 – FY2025

COGNITION THERAPEUTICS INC (CGTX) financials

Income statement

COGNITION THERAPEUTICS INC (CGTX) income statement, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Operating income-$17.4M-$28.6M-$43.6M-$50.7M-$54.0M-$47.8M
Net income-$7.84M-$11.7M-$21.4M-$25.8M-$34.0M-$23.5M
EPS (diluted)-$23.76-$3.13-$0.91-$0.86-$0.86-$0.32

Cash flow

COGNITION THERAPEUTICS INC (CGTX) cash flow, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-$3.43M-$3.63M-$18.5M-$16.0M-$28.5M-$24.6M
Capital expenditures$10.0K$27.0K$171K$147K$4.00K—
Free cash flow-$3.44M-$3.66M-$18.7M-$16.2M-$28.5M—

Balance sheet

COGNITION THERAPEUTICS INC (CGTX) balance sheet, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$5.19M$54.7M$41.6M$29.9M$25.0M$36.8M
Total assets$7.12M$59.1M$50.4M$35.2M$30.2M$48.4M
Total liabilities$19.9M$7.86M$10.2M$10.7M$11.5M$14.1M
Shareholders' equity-$68.2M$51.3M$40.2M$24.5M$18.8M$34.3M
Retained earnings-$68.2M-$94.0M-$115M-$141M-$175M-$199M
Shares (wtd avg diluted)508K5.19M23.6M30.0M39.7M72.8M

Every figure is extracted from COGNITION THERAPEUTICS INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

Does CGTX pay a dividend?
COGNITION THERAPEUTICS INC reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full CGTX analysis — verdict, score & filings →Is CGTX a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.